Table 4

Correlation of clinical features and laboratory values with tricuspid regurgitation velocity in patients with sickle cell disease

nPartial R*P
Hydroxyurea therapy 356 0.07 .2 
Hemoglobin 342 −0.32 < .001 
Hemolytic component 308 0.38 < .001 
Hemoglobin oxygen saturation 344 −0.11 .042 
Hemoglobin F percentage 173 0.15 .048 
Hemoglobin F category, 8% or higher versus lower than 8%† 173 0.26 .001 
Erythropoietin, natural log 335 0.34 < .001 
nPartial R*P
Hydroxyurea therapy 356 0.07 .2 
Hemoglobin 342 −0.32 < .001 
Hemolytic component 308 0.38 < .001 
Hemoglobin oxygen saturation 344 −0.11 .042 
Hemoglobin F percentage 173 0.15 .048 
Hemoglobin F category, 8% or higher versus lower than 8%† 173 0.26 .001 
Erythropoietin, natural log 335 0.34 < .001 
*

Adjusted for age, sex, site, and chronic transfusion program.

†

Ninety-four (54%) of the 173 patients had hemoglobin F of 8% or higher and 54% of these patients were on hydroxyurea.

View Large